Skyline Ventures is a venture capital firm founded in 1997, specializing in early-stage investments in healthcare and life science companies. The firm focuses on areas such as small molecule and protein therapeutics, medical devices, diagnostics, and technologies that facilitate drug discovery and life science research. With approximately $800 million under management, Skyline Ventures typically invests between $10 million and $15 million initially, aiming for total investments of $15 million to $35 million over the life of each portfolio company.

The firm seeks to lead or co-lead first or second institutional venture rounds and often takes a board seat to provide strategic guidance. Its investment approach is grounded in thorough evaluation of scientific principles, market potential, and management quality, reflecting a commitment to data-driven decision-making rather than speculative trends.